Otros idiomas Beam Therapeutics Inc.

Acciones

BEAM

US07373V1052

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
23,13 ^USD	+1,80 %		+8,19 %	-15,03 %

04/04	Un insider de Beam Therapeutics vendió acciones por valor de 581.617 dólares, según un reciente registro de la SEC	MT
04/04	Insider de Beam Therapeutics vendió acciones por valor de 734.805 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04/04
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04/04
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	27/02
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27/02
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27/02
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27/02
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	30/01
North American Morning Briefing : Microsoft Kicks -2-	30/01
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	29/01
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17/01
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Andy Bromberg, CEO de Beam: los ETF de Bitcoin, una financiarización alejada de la esencia original de las criptomonedas

30 de enero 2024 a las 20:21